Regulation of BCRP (ABCG2) and P-Glycoprotein (ABCB1) by Cytokines in a Model of the Human Blood–Brain Barrier

被引:3
作者
Birk Poller
Jürgen Drewe
Stephan Krähenbühl
Jörg Huwyler
Heike Gutmann
机构
[1] University Hospital of Basel,Department of Clinical Pharmacology and Toxicology
[2] University of Applied Sciences Northwestern Switzerland,Department of Pharmaceutical Technology
[3] Novartis Institute for Biomedical Research,Novartis Pharma AG
[4] TS,undefined
[5] DMPK,undefined
来源
Cellular and Molecular Neurobiology | 2010年 / 30卷
关键词
Blood–brain barrier; P-Glycoprotein; BCRP; Interleukin-6; Interleukin-1 beta; Tumor necrosis factor-alpha;
D O I
暂无
中图分类号
学科分类号
摘要
Brain capillary endothelial cells form the blood–brain barrier (BBB), a highly selective permeability membrane between the blood and the brain. Besides tight junctions that prevent small hydrophilic compounds from passive diffusion into the brain tissue, the endothelial cells express different families of drug efflux transport proteins that limit the amount of substances penetrating the brain. Two prominent efflux transporters are the breast cancer resistance protein and P-glycoprotein (P-gp). During inflammatory reactions, which can be associated with an altered BBB, pro-inflammatory cytokines are present in the systemic circulation. We, therefore, investigated the effect of the pro-inflammatory cytokines interleukin-1β (IL-1β), interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) on the expression and activity of BCRP and P-gp in the human hCMEC/D3 cell line. BCRP mRNA levels were significantly reduced by IL-1β, IL-6 and TNF-α. The strongest BCRP suppression at the protein level was observed after IL-1β treatment. IL-1β, IL-6 and TNF-α also significantly reduced the BCRP activity as assessed by mitoxantrone uptake experiments. P-gp mRNA levels were slightly reduced by IL-6, but significantly increased after TNF-α treatment. TNF-α also increased protein expression of P-gp but the uptake of the P-gp substrate rhodamine 123 was not affected by any of the cytokines. This in vitro study indicates that expression levels and activity of BCRP, and P-gp at the BBB may be altered by acute inflammation, possibly affecting the penetration of their substrates into the brain.
引用
收藏
页码:63 / 70
页数:7
相关论文
共 176 条
[11]  
Cisternino S(2003)Characterisation of the brain multidrug resistance protein (BMDP/ABCG2/BCRP) expressed at the blood–brain barrier Brain Res 971 221-231
[12]  
Mercier C(2007)Efflux transporters in ulcerative colitis: decreased expression of BCRP (ABCG2) and Pgp (ABCB1) Inflamm Bowel Dis 13 291-297
[13]  
Bourasset F(2007)Independent regulation of apical and basolateral drug transporter expression and function in placental trophoblasts by cytokines, steroids, and growth factors Drug Metab Dispos 35 595-601
[14]  
Roux F(2008)Differential effects of hydrocortisone and TNFalpha on tight junction proteins in an in vitro model of the human blood–brain barrier J Physiol 586 1937-1949
[15]  
Scherrmann JM(2008)Breast cancer resistance protein and P-glycoprotein expression in patients with newly diagnosed and therapy-refractory ulcerative colitis compared with healthy controls Digestion 78 154-162
[16]  
Cooray HC(2001)Molecular physiology and pathophysiology of tight junctions in the blood–brain barrier Trends Neurosci 24 719-725
[17]  
Blackmore CG(2009)Brain accumulation of dasatinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by elacridar treatment Clin Cancer Res 15 2344-2351
[18]  
Maskell L(2005)Investigation of efflux transport of dehydroepiandrosterone sulfate and mitoxantrone at the mouse blood–brain barrier: a minor role of breast cancer resistance protein J Pharmacol Exp Ther 312 44-52
[19]  
Barrand MA(2003)Clinical relevance of P-glycoprotein in drug therapy Drug Metab Rev 35 417-454
[20]  
Cordon-Cardo C(2005)Blood–brain barrier active efflux transporters: ATP-binding cassette gene family NeuroRx 2 86-98